Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01635907 · ClinicalTrials.gov registry record · Phase 2
Dovitinib in Neuroendocrine Tumors
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01635907: Completed Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01635907 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01635907, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors. This study will also further evaluate the safety of this drug.
Primary Outcome
using RECIST criteria
Interventions
- DRUG Dovitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-04-11 |
| Phase | Phase 2 |
What the finished NCT01635907 record still lists
NCT01635907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Dovitinib is the first listed.
NCT01635907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01635907 about?
NCT01635907 is a clinical study titled "Dovitinib in Neuroendocrine Tumors". This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors. This study will also further evaluate the safety of this drug.
What is the current status of trial NCT01635907?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2012-06. Estimated completion is 2016-04-11.
What interventions are being tested in trial NCT01635907?
The interventions under investigation include: Dovitinib (DRUG).
Who is sponsoring clinical trial NCT01635907?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01635907's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia